Jump to content

Balofloxacin

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Balofloxacin
Clinical data
ATC code
  • none
Identifiers
  • 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H24FN3O4
Molar mass389.427 g·mol−1
3D model (JSmol)
  • CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
  • InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27) checkY
  • Key:MGQLHRYJBWGORO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Balofloxacin (INN) is a fluoroquinolone antibiotic. It is sold under the brand name Q-Roxin in Korea, and under various names in India.[1] It is not approved by the FDA for use in the United States.

Pharmacodynamics

Balofloxacin is a fluoroquinolone that has a broad spectrum in vitro activity against a wide range of Gram-positive and Gram-negative bacteria, with enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae.[2] It functions by inhibiting the action of DNA-gyrase, preventing bacterial cells from reproducing or repairing themselves, resulting in cellular death.[3]

Side Effects

Vomiting, headache, dizziness, stomach pain, nausea, diarrhea and decreased liver function are the most common side effects. In rare cases, Balofloxacin can lead to or worsen tendinitis,[3] and muscular damage.[3]

See also

References

  1. ^ Alksne L (February 2003). "Balofloxacin Choongwae". Current Opinion in Investigational Drugs. 4 (2): 224–9. PMID 12669387.
  2. ^ "NCATS Inxight Drugs — BALOFLOXACIN". drugs.ncats.io. Retrieved 2022-07-28.
  3. ^ a b c "BALOFLOXACINhome: Uses, Side Effects and Medicines | Apollo Pharmacy". www.apollopharmacy.in. Retrieved 2022-07-28.